Point72 Middle East FZE’s Merck MRK Stock Holding History

Point72 Middle East FZE’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,323	Closed	-$3.2M	–	853
2023 Q4	$3.2M	Sell	29,323 -223,351	-88%	-$23.2M	0.09%	283
2023 Q3	$26M	Buy	+252,674	New	+$27.2M	0.85%	9
2023 Q2	–	Sell	-573	Closed	-$65.1K	–	1889
2023 Q1	$61K	Sell	573 -125,899	-100%	-$13.6M	﹤0.01%	1228
2022 Q4	$14M	Buy	+126,472	New	+$12.9M	0.61%	9

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Middle East FZE's MRK Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Merck (MRK) in Q1 2024, closing a stake of 29,323 shares — an estimated $3.2M sold.

Point72 Middle East FZE first reported a position in MRK in Q4 2022 and held it in 4 quarters. The position peaked at $26M in Q3 2023. 3,535 funds tracked by Wall St. Rank hold MRK as of Q1 2024.

Point72 Middle East FZE reported no remaining Merck position as of Q1 2024 after selling out during the quarter.
Point72 Middle East FZE sold 29,323 Merck shares in Q1 2024, an estimated $3.2M.
Point72 Middle East FZE first reported a position in Merck in Q4 2022 and held it in 4 quarters.
Point72 Middle East FZE's Merck position peaked at $26M in Q3 2023.
3,535 funds tracked by Wall St. Rank held Merck as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.